MedPath

The effects of nigella sativa oil on rheumatoid arthritis treatment

Phase 2
Conditions
Rheumatoid arthritis.
Rheumatoid arthritis, unspecified
Registration Number
IRCT2012120811689N1
Lead Sponsor
Vice chancellor for Research, Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

1) Subjects diagnosed with rheumatoid arthritis, based on American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) criteria; 2) Patients with mild to moderate rheumatoid arthritis; 3) Under treatment with disease-modifying antirheumatic drugs (Methotrexate, Hydroxychloroquine and Prednisolone less than 10 milligrams per day) and not receiving non-steroidal anti-inflammatory drugs or cytokine inhibitors; 4) Stable medication for at least 2 months prior to the interventions; 5) Have a body mass index (BMI) less than 40; 6) Willing to participate in the study; 7) Ages between 20 and 50.
Exclusion criteria: 1) Pregnant and lactating women; 2) Hormone therapy or receiving oral contraceptives; 3) Have diabetes mellitus, thyroid disorders, kidney or hepatic diseases or Cushing's syndrome; 4) Have inflammatory bowel disease or other inflammatory disorders; 5) Taking antioxidant and anti- inflammatory supplements 4 weeks prior to the interventions; 7) Being on a weight reduction diet; 7) Smoking or being exposed to cigarette smoke.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath